MedTrace Logo

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD

NCT07583849 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2026-05-13

No results posted yet for this study

Summary

To evaluate the efficacy and safety of a 12-week administration of HSK39004 inhalation powder in clinical trial participants with COPD

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

DRUG

HSK39004 Dry Powder Inhaler Simulant

HSK39004 Dry Powder Inhaler Simulants, administered via oral inhalation, 1 tablet each time, twice daily

DRUG

HSK39004 Dry Powder Inhaler-0.75mg

HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day

Sponsors & Collaborators

  • Haisco Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-24
Primary Completion
2027-09-30
Completion
2027-10-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07583849 on ClinicalTrials.gov